Inactive Instrument

Chromadex Corp Share Price OTC Bulletin Board

Equities

CDXC

US1710771007

Biotechnology & Medical Research

End-of-day quote OTC Bulletin Board
- USD - Intraday chart for Chromadex Corp
Sales 2024 * 96.57M 7.54B Sales 2025 * 114M 8.9B Capitalization 190M 14.84B
Net income 2024 * -1M -78.08M Net income 2025 * 4M 312M EV / Sales 2024 * 1.97 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 1.67 x
P/E ratio 2024 *
-314 x
P/E ratio 2025 *
40.2 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 64.21%
More Fundamentals * Assessed data
Managers TitleAgeSince
Chief Executive Officer 64 08/07/15
Founder 55 31/12/98
Director of Finance/CFO 44 -
Members of the board TitleAgeSince
Director/Board Member 63 26/03/17
Director/Board Member 49 08/08/22
Founder 55 31/12/98
More insiders
Chromadex Corp. is a global bioscience company. The Company is engaged in research on nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that is a key regulator of cellular metabolism and is found in every cell of the human body. Its segments include Consumer Products, Ingredients and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the Company's proprietary ingredients, commercialized as Tru Niagen, directly to consumers and distributors. The Ingredients segment develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The Ingredients segment provides Niagen in ingredient form to its strategic partners. The Analytical Reference Standards and Services segment offers the supply of phytochemical reference standards and other research and development services.
More about the company